Cognition Therapeutics Inc. Common Stock (CGTX)
Stock · NASDAQ · Health Care
$1.02as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support Reject93.1%
High Beta41.8%
Resistance level
$1.04
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, whic…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 14
- Website
- cogrx.com/
Fundamentals
- 1-day range
- $1.02$1.07
- Market cap
- $79.79M
- P/E (trailing)
- —
- P/E (forward)
- -4.64
- EPS (trailing)
- $-0.26
- Dividend yield
- —
- Beta
- 1.85
- Avg. volume
- 1.34M
52-week range
$0.5501$3.1
Next earnings: November 12, 2025 · EPS estimate $-0.11confirmed
Forecasts
3 analyst ratings
Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$4
+292.2%
Median
$3
+194.1%
Low
$3
+194.1%
Cognition Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CGTXCognition Therapeutics Inc. Common Stock$1.03▼ 3.30%Market cap $79.79MP/E —$0.5501$3.1
- ATRAAtara Biotherapeutics Inc. Common Stock$9.16▼ 0.97%Market cap $77.04MP/E —$3.92$19.15
- GNTAGenenta Science S.p.A. American Depositary Shares$1▼ 1.96%Market cap $67.99MP/E —$0.55$10
- PTHSPelthos Therapeutics Inc. Common Stock$24.46▼ 2.16%Market cap $93.29MP/E —$18.19$37.5
- IMAImageneBio Inc. Common Stock$5.34▲ 0.19%Market cap $63.61MP/E —$3.94$13.98
- KLRSKalaris Therapeutics Inc. Common Stock$4.03▼ 1.71%Market cap $96.36MP/E —$3.03$11.88
- XTNTXtant Medical Holdings Inc. Common Stock$0.4055▲ 22.88%Market cap $61.72MP/E 23.84$0.2702$0.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CGTX Cognition Therapeutics Inc. Common Stock | $79.79M | — | $1.03 | ▼ 3.30% | $0.5501$3.1 |
| ATRA Atara Biotherapeutics Inc. Common Stock | $77.04M | — | $9.16 | ▼ 0.97% | $3.92$19.15 |
| GNTA Genenta Science S.p.A. American Depositary Shares | $67.99M | — | $1 | ▼ 1.96% | $0.55$10 |
| PTHS Pelthos Therapeutics Inc. Common Stock | $93.29M | — | $24.46 | ▼ 2.16% | $18.19$37.5 |
| IMA ImageneBio Inc. Common Stock | $63.61M | — | $5.34 | ▲ 0.19% | $3.94$13.98 |
| KLRS Kalaris Therapeutics Inc. Common Stock | $96.36M | — | $4.03 | ▼ 1.71% | $3.03$11.88 |
| XTNT Xtant Medical Holdings Inc. Common Stock | $61.72M | 23.84 | $0.4055 | ▲ 22.88% | $0.2702$0.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) EstimateBenzinga · 8/6/2026
Insider Activity
Insider Actions →Acquired
154.2K
Disposed
8.6K
- BIOS Fund II QP, LP · June 17, 2026 · Grant25.0K
- Jack A. Khattar · June 17, 2026 · Grant25.0K
- Brett P. Monia · June 17, 2026 · Grant25.0K
- Peggy Wallace · June 17, 2026 · Grant25.0K
- Ellen B. Richstone · June 17, 2026 · Grant25.0K
- John Brendan Doyle · May 1, 2026 · Tax Withholding8.6K @ $1.28
- John Brendan Doyle · April 16, 2026 · Buy10.0K @ $1.13
- Anthony Caggiano · April 16, 2026 · Buy10.0K @ $1.11
- Lisa Ricciardi · April 16, 2026 · Buy9.2K @ $1.1
Institutional Ownership
March 31, 2026
- Total shares held
- 20.93M
- Total value held
- $15.74M
- Institutional holders
- 73
Top holders this quarter
- Unknown6.00M
- Unknown3.00M
- Unknown2.89M
- Unknown1.12M
- Unknown997.0K
- Unknown968.4K
- Unknown920.2K
- Unknown549.0K
- Unknown431.0K
- Unknown400.0K
See the full, filterable feed with live charts on the MarketWall dashboard.